Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

Lessons for cancer drug treatment from tackling a non-cancerous overgrowth syndrome

Abnormal activity of the enzyme PI3K can drive cancer growth, and mutations in a PI3K subunit can sometimes lead to non-cancerous overgrowth. A cancer drug that inhibits PI3K dramatically reduces such overgrowth.
  1. Robert K. Semple

    1. Robert K. Semple is in the Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4TJ, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Bart Vanhaesebroeck

    1. Bart Vanhaesebroeck is in the UCL Cancer Institute, University College London, London WC1E 6BT, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Researchers who investigate rare genetic conditions live in hope that the discovery of disease-causing mutations will lead swiftly to tailored treatments. Sadly, this is not often the case, because genetic defects usually cause impairments that are difficult or impossible to tackle using available medicines. Writing in Nature, Venot et al.1 now provide a rare exception to this rule. In severe non-cancerous overgrowth syndromes caused by mutations in an enzyme called PI3K, they show the beneficial effects of a PI3K-inhibitor drug that was initially developed to treat cancer. Their results bring the possibility of a transformative therapy for people with overgrowth conditions one step closer.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 558, 523-525 (2018)

doi: https://doi.org/10.1038/d41586-018-05365-w

References

  1. Venot, Q. et al. Nature 558, 540–546 (2018).

    Article  Google Scholar 

  2. Bianconi, E. et al. Ann. Hum. Biol. 40, 463–471 (2013).

    Article  PubMed  Google Scholar 

  3. Samuels, Y. et al. Science 304, 554 (2004).

    Article  PubMed  Google Scholar 

  4. Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Mol. Cancer Ther. 13, 2477–2488 (2014).

    Article  PubMed  Google Scholar 

  5. Kurek, K. C. et al. Am. J. Hum. Genet. 90, 1108–1115 (2012).

    Article  PubMed  Google Scholar 

  6. Lindhurst, M. J. et al. Nature Genet. 44, 928–933 (2012).

    Article  PubMed  Google Scholar 

  7. Rivière, J.-B. et al. Nature Genet. 44, 934–940 (2012).

    Article  PubMed  Google Scholar 

  8. Keppler-Noreuil, K. M. et al. Am. J. Med. Genet. A 167, 287–295 (2015).

    Article  Google Scholar 

  9. De Santis, M. C. et al. Cancers 9, 30 (2016).

    Article  Google Scholar 

  10. Castillo, S. D. et al. Sci. Transl. Med. 8, 332ra43 (2016).

    Article  PubMed  Google Scholar 

  11. Gerstung, M. et al. Preprint at bioRxiv https://doi.org/10.1101/161562 (2017).

  12. Jamal-Hanjani, M. et al. N. Engl. J. Med. 376, 2109–2121 (2017).

    Article  PubMed  Google Scholar 

  13. Yehia, L. & Eng, C. Endocr. Relat. Cancer https://doi.org/10.1530/ERC-18-0162 (2018).

    Article  Google Scholar 

  14. Sansregret, L., Vanhaesebroeck, B. & Swanton, C. Nature Rev. Clin. Oncol. 15, 139–150 (2018).

    Article  PubMed  Google Scholar 

  15. Ortega-Molina, A. et al. Cell Metab. 21, 558–570 (2015).

    Article  PubMed  Google Scholar 

  16. Bettedi, L. & Foukas, L. C. Biogerontology 18, 913–929 (2017).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

Bart Vanhaesebroeck is a consultant to Karus Therapeutics (Oxford, UK), iOnctura (Geneva, Switzerland) and Venthera (Palo Alto, California).

Subjects

Latest on:

Nature Careers

Jobs

  • Associate or Senior Editor (Immunology), Nature Communications

    The Editor in Immunology at Nature Communications will handle original research papers and work on all aspects of the editorial process.

    London, Beijing or Shanghai - Hybrid working model

    Springer Nature Ltd

  • Assistant Professor - Cell Physiology & Molecular Biophysics

    Opportunity in the Department of Cell Physiology and Molecular Biophysics (CPMB) at Texas Tech University Health Sciences Center (TTUHSC)

    Lubbock, Texas

    Texas Tech University Health Sciences Center, School of Medicine

  • Postdoctoral Associate- Curing Brain Tumors

    Houston, Texas (US)

    Baylor College of Medicine (BCM)

  • Professor

    Energy AI / Grid Modernization / Hydrogen Energy / Power Semiconductor Concentration / KENTECH College

    21, Kentech-gil, Naju-si, Jeollanam-do, Republic of Korea(KR)

    Korea Institute of Energy Technology

  • Professor in Macromolecular Chemistry

    The Department of Chemistry - Ångström conducts research and education in Chemistry. The department has 260 employees and has a turnover of 290 mil...

    Uppsala (Stad) (SE)

    Uppsala University

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links